News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

New ALK Inhibitor `Fantastically Active`

Al's Comment:

 AP26113 is a second-generation ALK and ROS1 inhibitor that seems in vitro to also have some activity against the activating epidermal growth factor receptor (EGFR) mutations and T790M.   It is in clinical trials for lung cancer. I mention it here because it looks like it may work for brain mets from lung cancer. They report: 4 out of 5 central nervous system deposits responding, and we are also getting duration of response data.


Posted on: 07/10/2013

 

New ALK Inhibitor 'Fantastically Active'

 

Go to: www.medscape.com/viewarticle/807208 for the full text. Unfortunately you may have to register to get in to view it.

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740